Create your Personal Health Record and unlock support built around you

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Learn more about HealthTree
Defining and Treating, or NOT Treating, Lower-risk MDS image

Defining and Treating, or NOT Treating, Lower-risk MDS

Sep 22, 2023
02:00PM - 03:00PM EDT
Online Event
Overview

MDS is a complicated disease to treat. Receiving a Lower-Risk MDS (LR-MDS) diagnosis comes with a lot of questions: Should I start treatment? Should we just watch and wait? What would treatment look like? What does “low risk” actually mean?

MDS specialist, Dr. Mikkael Sekeres, answers these questions and help us make sense of what an LR-MDS diagnosis looks like and what that means for patients. 
 

Agenda
12:00 PM
Introduction
Mary Arnett

Mary introduces the agenda for the event and featured speaker Mikkael Sekeres, MD.

12:05 PM
Presentation
Mikkael A. Sekeres, MD

Dr. Mikkael Sekeres defines what an LR-MDS diagnosis means and what treatment options are available to patients. 
 

12:40 PM
Questions and Answers
Audience

Type your questions in the chat and Dr. Sekeres will answer them! 

Speakers & Moderators
Healthtree contact Mary Arnett

Mary Arnett

Mary joined HealthTree as the HealthTree for MDS Program Manager in 2022. She is passionate about giving power to patients through knowledge and health education. If she can help one patient feel more confident participating in discussions with their healthcare team and making treatment decisions, she will feel like she has succeeded. When she isn't advocating for MDS patients, she loves being an aunt, attending concerts, and experimenting with new recipes in the kitchen.
Healthtree contact Mikkael A. Sekeres, MD

Mikkael A. Sekeres, MD

Dr. Mikkael A. Sekeres joined the University of Miami Health System and Sylvester Comprehensive Cancer Center as Chief of the Division of Hematology. His research focuses on patients with myelodysplastic syndromes (MDS) and older adults with acute myeloid leukemia (AML). He has been the national and international primary study investigator on dozens of phase I/II/III clinical trials. He is the author or co-author of over 400 manuscripts and 600 meeting abstract. He is a frequent essayist for The New York Times and has written 8 books. He is on the Executive Committee of the American Society of Hematology and a member of the American Society of Clinical Oncology and the Southwest Oncology Group —Leukemia Committee.